Funding for this research was provided by:
Canadian Institutes of Health Research (PJT-156114)
Received: 16 January 2019
Accepted: 12 March 2019
First Online: 1 April 2019
Ethics approval and consent to participate
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of secondary analysis formal consent is not required.
: Not applicable.
: KR is the founder, President, Chief Science Officer and majority shareholder of DGI Clinical Inc., a company that had a contractual agreement with Baxalta US Inc., now part of Shire, to study individualized outcome measures in haemophilia. LM is a Mitacs postdoctoral fellow whose industrial co-sponsor is DGI Clinical, Halifax, Nova Scotia, Canada. JCR has received investigator-initiated research grant support, has served as a consultant, received travel support, and served on a speaker’s bureau for Baxalta US Inc. and Shire. MD is an employee and shareholder of Shire.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.